SCOTUS Rules That Mifepristone Can Continue to be Prescribed by Telehealth and Sent in the Mail

On Thursday, May 14, 2026, the Supreme Court of the United States (SCOTUS) ruled that mifepristone (Mifeprex; Danco Laboratories) can continue to be prescribed by telehealth and sent to patients in the mail. The ruling comes after weeks of legal turmoil that left patients, health care providers, and pharmacists in a state of uncertainty about how and whether they could access and distribute the drug.¹

On May 4, 2026, Justice Samuel A. Alito Jr paused a lower-court ruling from Friday, May 1, 2026, that prevented providers from prescribing mifepristone via telehealth and shipping it to patients, an action that sparked confusion among health care providers and patients.² The 2 manufacturers of mifepristone had asked SCOTUS to intervene after the US Court of Appeals for the Fifth Circuit restricted access to the medication nationwide. Although SCOTUS’s brief order means that the Fifth Circuit’s decision will remain blocked—potentially for months—litigation will continue in the lower courts, and the issue could eventually return back to the high court.¹

What This Means for Patients and Pharmacists

For now, patients can continue to access mifepristone the way most have in recent years: through a telehealth consultation with a certified provider, followed by delivery of the medication through the mail or pickup at a certified pharmacy—no in-person visit required.^1,2

That access matters enormously in the current landscape. About two-thirds of pregnancy terminations in the United States are obtained through the 2-drug regimen of mifepristone and misoprostol, and the availability of medication abortion by mail has blunted the impact of in-clinic abortion bans that many states have enacted since the 2022 SCOTUS decision overturning Roe v Wade. Separate “shield laws” that are enacted by some states have also legally protected providers who prescribe mifepristone via telehealth to patients living in states with abortion bans.^1,2

For pharmacists, dispensing authority is preserved for now. Certified pharmacies can continue to dispense mifepristone on prescriptions issued by certified telehealth providers, including by mail. That pipeline remains intact while litigation continues. Regardless of the court's order, the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program requirements remain fully in effect. This means that²:

• Only certified pharmacies may dispense mifepristone;
• Pharmacies must complete a pharmacy agreement form to become certified;
• The patient agreement form must be signed before dispensing;
• Mifepristone must be shipped with a trackable shipping service; and
• Dispensing must happen in a timely manner.

Importantly, the ruling doesn't erase the individual state-level regulations. Some states have shield laws protecting pharmacists and health care providers who dispense via telehealth to patients in banned states, whereas others have restrictions that go beyond federal rules. Pharmacists need to know where their state stands independently of what SCOTUS does at the federal level.

Additionally, the pause emphasizes the ongoing legal and regulatory uncertainty surrounding access to mifepristone and the broader landscape of reproductive health care within the US. The case goes back to the Fifth Circuit for a full merits review, meaning the rules could change again. Pharmacists should treat the current access window as provisional, not permanent. As access pathways continue to shift—particularly through telehealth and certified pharmacy dispensing—pharmacists remain vital in maintaining continuity of care, providing accurate counseling, and supporting patients in a complex, changing treatment landscape.

What Comes Next

Thursday's ruling is not a final resolution. Although SCOTUS has preserved access on an interim basis while litigation continues, the long-term telehealth access to mifepristone remains unsettled. The case will return to the Fifth Circuit for a full review of Louisiana's arguments. The legal landscape surrounding medication pregnancy termination remains deeply volatile, and providers and pharmacists are being urged to stay informed about evolving policies, REMS requirements, and state-specific regulations as the case continues. Essentially, the ruling maintains the status quo but offers no guarantee of permanence.

“We are relieved that access to mifepristone remains protected for now, but this should never have been on the table in the first place,” Serra Sippel, executive director of The Brigid Alliance, said in AP News. “Patients and providers should not be forced to wait on court rulings to know whether people can access critical health care.”³

REFERENCES

1. Marimow AE. Supreme Court Allows Abortion Pill Access by Mail to Continue. The New York Times. May 14, 2026. Accessed May 15, 2026. https://www.nytimes.com/2026/05/14/us/politics/supreme-court-abortion-pill.html

2. McGovern G. SCOTUS Temporarily Restores Access to Mifepristone via Telehealth, Mail, and Pharmacies. Pharmacy Times. May 4, 2026. Accessed May 15, 2026. https://www.pharmacytimes.com/view/scotus-temporarily-restores-access-to-mifepristone-via-telehealth-mail-and-pharmacies

3. Sherman M, Mulvihill G, Perrone M. Supreme Court preserves access to widely used abortion pill, while lawsuit plays out. AP News. May 14, 2026. Accessed May 15, 2026. https://apnews.com/article/supreme-court-mifepristone-abortion-louisiana-637acaa2f233de067e3756bea50bd723